Register for upcoming (live) or recorded webinars, choose by topic, or search by keyword to find webinars of interest.


Biosimilars are so-called “generic” forms of biologic drugs. Generally, they are larger molecular drugs derived from, or made by, an organism for which the patent for the original biologic drug has expired, and subsequently, a similar molecule can be designed and marketed. There are a wide range of topics covered in our webinars under the term biosimilars – from testing immunogenicity of biosimilar drugs and assessing the efficacy of biosimilars in clinical trials, to conducting safety assessments of biosimilars and meeting FDA guidelines.